Main Article Content
Objective: To evaluate the efficacy of dual therapy of Sofosbuvir and Ribavirin among treatment-naive and non-responders
of Interferon based antiviral regimens against HCV genotype 3a infected patients.
Material & Methods: A longitudinal study was conducted on 100 HCV genotype 3a infected patients from December
2016 to September 2017. Patients were initially divided into two groups including Group-A (n=50/100) as treatment
naive, and Group-B (n=50/100) including non-responders. All patients received Sofosbuvir and RBV for 24weeks. HCV
genotype was determined using Type-specific nested PCR based genotyping assay. Viral RNA was detected using
qualitative or real-time PCR.
Results: After 4 weeks of treatment, HCV RNA was undetectable in 100 of Group A patients, while Group B patients
achieved 92% RVR. SVR12 was 96% in treatment naïve Group A patients, while Group B patients achieved an SVR12 of
90%. There were no significant differences in the SVR12 rates between the two treatment groups (Pearson Chi-Square
test, p-value >0.05). The association of RVR and SVR12 was found statistically significant (Pearson Chi-Square test,
Conclusion: Sofosbuvir and RBV is highly effective among the treatment-naive and previously treated chronic HCV
genotype 3a infected patients.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
CopyRight . © 2008-2020 Khyber Medical College Peshawar | All Rights Reserved